ATARA BIOTHERAPEUTICS, INC. Restricted Cash and Cash Equivalents, Noncurrent
ATARA BIOTHERAPEUTICS, INC. (ATRA) had Restricted Cash and Cash Equivalents, Noncurrent of $1.20 million as of 2018-09-30, per its 10-Q filed 2018-11-06.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2018-11-06
- 2018-09-30: Restricted Cash and Cash Equivalents, Noncurrent $1.20M.
- 2018-06-30: Restricted Cash and Cash Equivalents, Noncurrent $1.20M.
- 2018-03-31: Restricted Cash and Cash Equivalents, Noncurrent $1.20M.
- 2017-12-31: Restricted Cash and Cash Equivalents, Noncurrent $1.20M.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent |
|---|---|
| 2018-09-30 | $1.20M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $1.20M 10-Q · filed 2018-08-01 |
| 2018-03-31 | $1.20M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $1.20M 10-Q · filed 2018-11-06 |
| 2017-09-30 | $1.20M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $1.20M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $1.20M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $0.00 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |